Core Insights - First Principles Partners specializes in equity research focused on technology, innovation, and sustainability investment, utilizing a unique approach that breaks down complex problems to their basic elements [1] Group 1: Company Overview - First Principles Partners has a strong background in investment, private equity, and venture capital, demonstrating a proven track record of delivering strong returns [1] - The company emphasizes emerging technologies and sustainable investing, highlighting the intersection of innovation and finance [1] Group 2: Research Approach - The "First Principles" approach allows the company to uncover overlooked investment opportunities by simplifying complex financial and technological problems [1] - The company is committed to sharing insights with a wider audience and learning from fellow investors to drive positive change [1]

The Hague, May 8, 2025 - Aegon has today published the agenda for its Annual General Meeting of Shareholders (AGM), scheduled for Thursday, June 12, 2025. The related meeting materials, including the agenda, are now available on our website. At the AGM, the Board of Directors will present the 2024 Annual Accounts and propose a final dividend of EUR 0.19 per common share. This brings the total dividend for 2024 to EUR 0.35 per common share. The agenda further includes several proposals concerning the composi ...

Core Points - Knight Therapeutics Inc. held its Annual General Meeting of Shareholders virtually in Montreal, Quebec, where key voting results were announced [1] Group 1: Election of Directors - All director nominees listed in the Management Information Circular dated April 4, 2025, were elected as Directors of the Corporation [2] - Jonathan Ross Goodman received 59,911,976 votes (96.70% for) and 2,041,772 votes (3.30% against) [2] - James C. Gale received 61,421,942 votes (99.14% for) and 531,806 votes (0.86% against) [2] - Samira Sakhia received 61,868,351 votes (99.86% for) and 85,397 votes (0.14% against) [2] - Robert N. Lande received 61,742,628 votes (99.66% for) and 211,120 votes (0.34% against) [2] - Michael J. Tremblay received 59,558,152 votes (96.13% for) and 2,395,596 votes (3.87% against) [2] - Nicolás Sujoy received 61,749,390 votes (99.67% for) and 204,358 votes (0.33% against) [2] - Janice Murray received 61,750,229 votes (99.67% for) and 203,519 votes (0.33% against) [2] Group 2: Appointment of External Auditors - Ernst & Young LLP was appointed as external auditors for the next year with 62,087,609 votes (99.60% for) and 248,512 votes (0.40% withheld) [3] Group 3: Employee and Director Share Purchase Plan - The resolution to renew unallocated rights under the Corporation's employee and director share purchase plan was approved with 54,409,705 votes (87.82% for) and 7,544,043 votes (12.18% against) [4] Group 4: Company Overview - Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, focusing on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America [5] - The company's Latin American subsidiaries operate under United Medical, Biotoscana Farma, and Laboratorio LKM [5] - Knight Therapeutics Inc.'s shares are traded on TSX under the symbol GUD [5]

Core Points - GENFIT, a biopharmaceutical company focused on rare and life-threatening liver diseases, announced its Combined Shareholders Meeting scheduled for June 17, 2025 [1] - The meeting will be held at the Faculty of Pharmaceutical Sciences in Lille, France, and will be accessible via live broadcast on the company's website [3] - Shareholders will have the option to vote online through the VOTACCESS platform, with a tutorial provided for guidance [4] Company Overview - GENFIT is a late-stage biopharmaceutical company with over two decades of experience in liver disease research and development [5] - The company has a diversified R&D portfolio, focusing on Acute-on-Chronic Liver Failure (ACLF) and other serious diseases, with five assets under development in its ACLF franchise [5] - GENFIT's expertise includes the accelerated approval of its drug Iqirvo® (elafibranor) for Primary Biliary Cholangitis (PBC) by major regulatory authorities [5] - The company also has a diagnostic franchise targeting metabolic dysfunction-associated steatohepatitis (MASH) and blood ammonia levels [5] - GENFIT is headquartered in Lille, France, with additional offices in Paris, Zurich, and Cambridge, MA, and is listed on both Nasdaq and Euronext [5]

Core Viewpoint - Mercury General Corporation (MCY) reported a narrower operating loss of $2.29 per share for Q1 2025, compared to a loss of $4.00 estimated by Zacks Consensus, and a prior-year operating income of 78 cents per share [1] Operational Update of MCY - Total operating revenues for the quarter were $1.4 billion, reflecting a 10.9% year-over-year increase, although it missed the consensus estimate by 4.4% [2] - Net premiums earned rose 10% year over year to $1.3 billion, falling short of the Zacks Consensus Estimate of $1.4 billion [2] Investment Income and Expenses - Net investment income before income taxes increased by 25.3% year over year to $81.5 million, surpassing the Zacks Consensus Estimate of $65 million [3] - Total expenses rose 29.6% year over year to $1.5 billion, driven by higher losses, loss adjustment expenses, and policy acquisition costs [3] Catastrophe Losses and Ratios - Catastrophe losses net of reinsurance amounted to $447 million, significantly higher than a loss of $72 million in the prior-year quarter, primarily due to Southern California wildfires [4] - The combined ratio deteriorated by 1,830 basis points year over year to 119.2, with the loss ratio worsening by 1,760 basis points to 95.1 [4] Financial Update of MCY - As of March 31, 2025, total assets were $9 billion, an increase of 8.6% from the end of December 2024, with a cash balance of $1.2 billion, up 78.3% [5] - Shareholder equity decreased by 6.5% to $1.8 billion, and book value per share was $32.87, down 6.4% year over year [6] Dividend Update - The board of directors declared a quarterly dividend of 31.75 cents per share, payable on June 26, 2025, to shareholders of record as of June 12, 2025 [7] MCY Zacks Rank - MCY currently holds a Zacks Rank of 3 (Hold) [8]

Company Overview - JFB Construction Holdings is a construction company focused on commercial, retail, and residential property development [1][4] - The company has extensive experience in building multifamily communities, shopping centers, national franchises, and over 2 million square feet of commercial and retail space [4] Recent Developments - JFB Construction has signed a construction contract valued at $18 million to develop a new Courtyard by Marriott with 117 rooms in Olive Branch, Mississippi [2][3] - Construction is scheduled to commence by early June 2025 [2] Strategic Goals - The CEO of JFB Construction, Joseph F. Basile, III, stated that this project represents a major milestone for the company and aligns with its future goals [3] - The company is actively involved in the land acquisition process and holds an ownership position in the project location, indicating a commitment to hospitality development [3]

Core Points - Suncor Energy held its Annual General Meeting in Calgary, with approximately 70.29% of outstanding common shares represented [1] - The company is Canada's leading integrated energy company, involved in oil sands development, offshore oil production, petroleum refining, and renewable energy investments [3] Shareholder Votes - Eleven board members were elected, with voting percentages for individual directors ranging from 94.68% to 99.19% [5] - KPMG LLP was appointed as Suncor's auditors [5] - Management's approach to executive compensation was approved with 97.06% of shares voting in favor [5] - A resolution to commission a report on the impacts and costs of achieving Net Zero by 2050 was denied, with 98.50% voting against it [5]

Core Viewpoint - General Motors (GM) anticipates a significant impact from tariffs, estimating a potential loss of $5 billion, yet remains optimistic about profitability in 2025 [1] Group 1 - GM is adapting to the challenges posed by tariffs by shifting some production to the U.S. [1] - The company is leveraging its strong market share in large trucks and SUVs to maintain profitability [1]

Group 1 - The company Technip Energies announced that all resolutions submitted for shareholder approval at the 2025 annual general meeting were adopted [1] - Shareholders approved all resolutions with over 83% of the votes, including the adoption of the 2024 financial statements and a proposed dividend of EUR 0.85 per outstanding ordinary share for the 2024 financial year [2] - The 2024 Remuneration Report was adopted with 88.73% of votes in favor [2] Group 2 - Technip Energies is a global technology and engineering powerhouse with leadership positions in LNG, hydrogen, ethylene, sustainable chemistry, and CO2 management [3] - The company generated revenues of €6.9 billion in 2024 and is listed on Euronext Paris [4] - Technip Energies employs over 17,000 people across 34 countries, committed to bridging prosperity with sustainability [4]

Outcome of Syensqo’s 2025 Annual General Meeting Brussels, Belgium – May 6, 2025 - 17:45 CEST Syensqo held its Annual General Shareholders’ Meeting today. Shareholders voted in favor of all the resolutions proposed. Rosemary Thorne, Chair of the Board of Directors, reflected on the company's first full year post-demerger, highlighting strategic initiatives undertaken in 2024 to strengthen its foundation amid macroeconomic uncertainties. Key initiatives included cost controls, capacity investments, a share ...